A1 Refereed original research article in a scientific journal
Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
Authors: Harmanen, Minna; Hujo, Mika; Sund, Reijo; Sorigue, Marc; Khan, Madiha; Prusila, Roosa; Klaavuniemi, Tuula; Kari, Esa; Jantunen, Esa; Sunela, Kaisa; Rajamäki, Aino; Alanne, Erika; Kuitunen, Hanne; Sancho, Juan‐Manuel; Jukkola, Arja; Rönkä, Aino; Kuittinen, Outi.
Publisher: Wiley
Publication year: 2025
Journal: Hematological Oncology
Journal name in source: Hematological Oncology
Article number: e70024
Volume: 43
Issue: 1
ISSN: 0278-0232
eISSN: 1099-1069
DOI: https://doi.org/10.1002/hon.70024
Web address : https://doi.org/10.1002/hon.70024
Mantle cell lymphoma is a rare type of B-cell lymphoma, which is considered incurable yet treatable. In recent years, the treatment options of mantle cell lymphoma have multiplied, and the focus of treatment is expected to shift from traditional chemoimmunotherapy toward precision medicine. However, this development is hindered by the high costs of targeted therapies. To provide a baseline for future assessment of costs and benefits of new and emerging MCL treatments, we established a predictive simulated model of lifetime treatment trajectories based on a retrospective cohort of chemoimmunotherapy era patients diagnosed and treated between the year 2000 and 2020.
Funding information in the publication:
Minna Harmanen has received financial support from following organizations: Finnish Cancer Foundation (personal research grant); North Savonian Cancer Association (personal research grant); and Northern Finland Healthcare Support Foundation (personal working grant).
Aino Rönkä and Outi Kuittinen collaborated for this work at equal contribution.
